|
注册号: Registration number: |
ChiCTR2500112232 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-11 17:11:44 |
|
注册时间: Date of Registration: |
2025-11-11 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
布比卡因脂质体与罗哌卡因在肌间沟入路臂丛神经阻滞中的术后镇痛效果评价:随机对照试验 |
|
Public title: |
Evaluation of postoperative analgesic effects of liposomal bupivacaine and ropivacaine in Interscalene brachial plexus block: a randomized controlled trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
布比卡因脂质体与罗哌卡因在肌间沟入路臂丛神经阻滞中的术后镇痛效果评价:随机对照试验 |
|
Scientific title: |
Evaluation of postoperative analgesic effects of liposomal bupivacaine and ropivacaine in Interscalene brachial plexus block: a randomized controlled trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
唐倩倩 |
研究负责人: |
王长明 |
|
Applicant: |
Qianqian Tang |
Study leader: |
Changming Wang |
|
申请注册联系人电话: Applicant telephone: |
+86 178 6653 3118 |
研究负责人电话:
Study leader's |
+86 177 0248 6100 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
3197785219@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
teamwangcm@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
辽宁省沈阳市沈河区文艺路33号 |
研究负责人通讯地址: |
辽宁省沈阳市沈河区文艺路33号 |
|
Applicant address: |
33 Wenyi Road, Shenhe District, Shenyang, Liaoning |
Study leader's address: |
33 Wenyi Road, Shenhe District, Shenyang, Liaoning |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
辽宁省人民医院 |
||
|
Applicant's institution: |
Liaoning Provincial People's Hospital |
||
|
研究负责人所在单位: |
辽宁省人民医院 |
||
|
Affiliation of the Leader: |
Liaoning Provincial People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2025)H044号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
辽宁省人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Liaoning Provincial People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-09-10 00:00:00 | ||
|
伦理委员会联系人: |
郑凯 |
||
|
Contact Name of the ethic committee: |
Kai Zheng |
||
|
伦理委员会联系地址: |
辽宁省沈阳市沈河区文艺路33号 |
||
|
Contact Address of the ethic committee: |
33 Wenyi Road, Shenhe District, Shenyang, Liaoning |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 24 2401 6585 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
辽宁省人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Liaoning Provincial People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
辽宁省沈阳市沈河区文艺路33号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
33 Wenyi Road, Shenhe District, Shenyang, Liaoning |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
None |
||||||||||||||||||||||
|
研究疾病: |
肩袖损伤 |
||||||||||||||||||||||
|
Target disease: |
Rotator Cuff Injury |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
比较超声引导下肌间沟臂丛神经阻滞使用布比卡因脂质体与罗哌卡因对肩关节镜手术患者的术后镇痛效果,旨在为临床使用提供参考。 |
||||||||||||||||||||||
|
Objectives of Study: |
Comparing the postoperative analgesic effects of interscalene brachial plexus block using liposomal bupivacaine and ropivacaine under ultrasound guidance on patients undergoing shoulder arthroscopy surgery, with the aim of providing reference for clinical use. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
拒绝参与,手术部位感染,现有解剖异常,对研究药物过敏史,周围神经存在病变,肌肉骨骼和桡神经或尺神经病变,精神障碍,凝血功能障碍,BMI>35 kg/m^2,严重肺部疾病,心功能不全,脑血管疾病,肝功能障碍,严重肾功能不全,孕妇或哺乳期妇女,长期使用阿片类药物者以及近期3个月之内参与过其他临床试验者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Refusal to participate, surgical site infection, existing anatomical abnormalities, history of drug allergies to research drugs, peripheral nerve lesions, musculoskeletal and radial or ulnar nerve lesions, mental disorders, coagulation dysfunction, BMI>35 kg/m^2, Severe lung disease, heart failure, cerebrovascular disease, liver dysfunction, severe renal dysfunction, pregnant or lactating women, long-term use of opioid drugs, and those who have participated in other clinical trials within the past 3 months. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-11-01 00:00:00至 To 2027-09-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-12-01 00:00:00 至 To 2027-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由研究者使用SPSS25.0软件对78例患者进行随机分组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The researchers used spss25.0 software to randomly divide 78 patients. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
本试验为双盲试验,所有参与本研究的患者、数据收集者和分析人员、外科医生对治疗分配一无所知。 |
|
Blinding: |
This was a double-blind trial and all patients, data collectors and analysts, and surgeons involved in this study had no knowledge of the treatment assignment. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
中国临床试验注册中心,www.chictr.org.cn |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
China clinical trial registration center, www.chictr.org.cn |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
ResMan |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
ResMan |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |